NCT01780662 · OUTCOME

Number of Patients With FcyRIIIa-158 V/F (Valine/Phenylalanine) Polymorphism

Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma · Source last updated 2021-10-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: COUNT_OF_PARTICIPANTS
Unit: Participants
Interval / dispersion: Not reported
Time frame: From the end of first dose to the end of last dose (Up to 13 Months)

What was measured

Among patients who received 1.8mg/kg dose, the frequency of the FcγRIIIa-158 V/F polymorphism are described.

Analysis population: 4 eligible patients did not consent for genetic studies.

Groups in this outcome

Dose 1.8mg/kg

Evaluable patients with received dose of 1.8mg/kg

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Dose 1.8mg/kg	41

Reported measurements

Homozygous FF- Phenylalanine

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Dose 1.8mg/kg	22	Not reported	Not reported	Not reported	Not reported

Heterozygous FV- Valine/Phenylalanine

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Dose 1.8mg/kg	14	Not reported	Not reported	Not reported	Not reported

Homozygous VV- Valine

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Dose 1.8mg/kg	5	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
22
title
Homozygous FF- Phenylalanine
categories
measurements
group Id
OG000
value
14
title
Heterozygous FV- Valine/Phenylalanine
categories
measurements
group Id
OG000
value
5
title
Homozygous VV- Valine

denoms

counts
group Id
OG000
value
41
units
Participants

description

Among patients who received 1.8mg/kg dose, the frequency of the FcγRIIIa-158 V/F polymorphism are described.

groups

description
Evaluable patients with received dose of 1.8mg/kg
id
OG000
title
Dose 1.8mg/kg

param Type

COUNT_OF_PARTICIPANTS

population Description

4 eligible patients did not consent for genetic studies.

reporting Status

POSTED

time Frame

From the end of first dose to the end of last dose (Up to 13 Months)

title

Number of Patients With FcyRIIIa-158 V/F (Valine/Phenylalanine) Polymorphism

type

SECONDARY

unit Of Measure

Participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice